ILLUMINA INC. DL-,01 (ILU.MU)
| Previous Close | 222.25 |
| Open | 223.90 |
| Bid | 225.50 x 0 |
| Ask | 229.80 x 0 |
| Day's Range | 223.90 - 223.90 |
| 52 Week Range | 199.35 - 442.70 |
| Volume | |
| Avg. Volume | 2 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Reuters
EU court to rule July 13 on Illumina challenge of EU review of Grail -sources
A European court will decide on July 13 whether U.S. life sciences company Illumina's $8 billion cash-and-stock takeover of Grail should be scrutinised by EU antitrust regulators, people familiar with the matter said on Wednesday. The case coincides with the European Commission seeking to expand its power to examine big companies' acquisitions of start-ups aimed at shutting down nascent rivals, with the focus on tech and pharma deals. The Luxembourg-based General Court, Europe's second-top court, declined to comment on the date of its ruling.
- Zacks
Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
- News Direct
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients With Rare Genetic Mutations to Targeted Therapy
First companion diagnostic claim for Illumina's TruSight™ Oncology Comprehensive (EU) test enables targeted therapy with Bayer's VITRAKVI® (larotrectinib) for patients with NTRK fusion cancer
